According to the latest report, Indian saline solution market reached a value of US$ 518 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 925 Million by 2027, exhibiting at a CAGR of 10.0% during 2022-2027.
A saline solution refers to a supplement fluid comprising of electrolytes, water, and sugar. It is given to patients according to their medical requirements, age, and body size for maintaining electrolyte balance. A saline solution is either applied topically or used intravenously to administer drugs and essential food nutrients in the body when an individual is unable to consume the same orally. Some of the product variants include normal saline, Ringer’s lactate solution, dextrose, etc. Consequently, saline solutions are extensively utilized in hospitals, ambulatory surgical centers, clinics, etc., across India.
The rising prevalence of several chronic ailments, including cardiovascular diseases (CVDs), neurological disorders, cancer, etc., which usually require surgeries and hospitalization, is primarily driving the India saline solution market. Besides this, the growing consumer consciousness towards early disease detection and effective treatments and the significant improvements in medical infrastructures across the country are further catalyzing the market growth.
Get a PDF Sample for more detailed market insights: https://www.imarcgroup.com/india-saline-solution-market/requestsample
Moreover, the increasing participation of individuals in physical activities is stimulating the adoption of saline solutions for treating chronic dehydration that can cause appetite loss, fatigue, irritability, etc. This, in turn, is also augmenting the product demand. Additionally, the inflating need for providing essential nutrients to patients admitted to the intensive care units (ICUs), on account of the sudden outbreak of the COVID-19 pandemic, is also positively influencing the market growth. Apart from this, the introduction of easy-to-use and portable packaging materials that can be used as drips in homecare centers is anticipated to fuel the India saline solution market over the forecasted period.
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
Abaris Healthcare, Aculife Healthcare Pvt. Ltd. (Nirma Chemical Works Pvt Ltd.), Albert David limited, Althea Pharma, Amanta Healthcare, B Braun India Pvt. Ltd., Eurolife Healthcare Pvt. Ltd., Fresenius Kabi India Pvt. Ltd. (Fresenius Kabi AG) and Otsuka Pharmaceutical Co. Ltd. (Otsuka Holdings Co.,Ltd).
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/india-saline-solution-market
The report has segmented the market on the basis of product type, packaging type, end-use and application.
Breakup by Product Type:
Normal Saline
Ringer’s Lactate Solution
Dextrose
Others
Breakup by Packaging Type:
500 ml
100 ml
1000 ml
250 ml
Breakup by End-Use:
Hospitals
Clinics
Ambulatory Surgery Center
Home Care Center
Others
Breakup by Application:
IV Drips
Nasal Drops
Cleaning Wounds
Eye Drops
NaCl Inhalation
Others
Breakup by Region:
South India
North India
West & Central India
East India
If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
Key highlights of the report:
- Market Performance (2016-2021)
- Market Outlook (2022- 2027)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.